about
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding TrialProtocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive studySurgeon-specific mortality data disguise wider failings in delivery of safe surgical services.Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.Likelihood estimation for a longitudinal negative binomial regression model with missing outcomes.Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.Predictors for radiological damage in psoriatic arthritis: results from a single centre.Twist-drill craniostomy with hollow screws for evacuation of chronic subdural hematoma.Random variation in rectal position during radiotherapy for prostate cancer is two to three times greater than that predicted from prostate motion.Estimating causal effects using prior information on nontrial treatments.Comparison of analysis approaches for multi-level vascular imaging data.Using the UK renal registry for a clinical trial in dialysis patients: the example of SIMPLIFIED.Simulation work in adaptive dose-finding designs to identify dose-intervals that achieve targets in multiple endpoints.Interim sample size re-estimation in the IIVOP trial.Addressing the barriers to implementing model based designs in dose escalation studies.Adaptive dose-finding designs to identify multiple doses that achieve multiple response targets.Model selection and sample size adaptation: HYPAZ trial.ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.rpsftm: An R Package for Rank Preserving Structural Failure Time Models.Low absolute bioavailability of oral naloxone in healthy subjects.Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.Protocol of a randomised controlled trial of real-time continuous glucose monitoring in neonatal intensive care 'REACT'.The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetesTreatment-Related Morbidity and Hospital League Tables: Experience from a National Audit of Radiotherapy-Induced Morbidity in Cervical CarcinomaRadiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trialNational Audit of the Management and Outcome of Carcinoma of the Cervix Treated with Radiotherapy in 1993Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II TrialsDelay in diagnosis in breast cancerLow-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trialTargeting glucose control in preterm infants: pilot studies of continuous glucose monitoringTheory of general balance applied to step wedge designs.Instrumental variables and interactions in the causal analysis of a complex clinical trialBounds on the covariate-time transformation for competing-risks survival analysisCombined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trialNaloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteersUltrasound elastography as an adjuvant to conventional ultrasound in the preoperative assessment of axillary lymph nodes in suspected breast cancer: a pilot studyStepped wedge cluster randomized trials are efficient and provide a method of evaluation without which some interventions would not be evaluated
P50
Q28554636-060CF8CA-4216-4554-91B7-06F527773B62Q28604189-B14BFD8F-039C-4788-ACBD-2F4E9323E8EDQ30865411-9466C7E1-00E5-4D7F-AB59-FA30DF5982DAQ33744839-275A289C-1310-4ECE-A5F0-1DB5D32F84C3Q34344248-E2B376D3-1285-444F-9822-4DF9832FA8F3Q34401622-E2D479E1-57D0-42AD-9DF7-BBCE656C1568Q34628073-050099B0-BBE5-40F5-9727-2C6DD616CED2Q35760034-60125B66-2A99-46D2-8BF0-F2943EA738FBQ38208438-EF14F1EF-0467-4DE5-8470-001CDC805E7AQ42202252-CE7667AB-2703-4BBA-8FE3-388360B92626Q42206341-A7C8CD4B-3426-4819-85F0-4634B0A0A28EQ45958050-1AF13ED6-8B98-47C7-A0B9-83F5E2194E11Q45979550-41EEA37E-8331-4640-B298-EA92FE9B846BQ45992011-F40450BA-AA81-40F5-8233-9FB48E01EC7DQ45993924-D5C71FC9-ECEE-4365-B4BB-04173EFCF64CQ45994130-53129D05-F5CD-4B6A-9862-5FE9B60D5711Q46414523-B21BEB3D-B075-4889-8EB7-661D1F92559DQ46743933-5AFBAF19-3A9B-4E05-BB15-A4A07B474805Q47578443-3B33DE60-D979-49F7-A662-4B51255E00B4Q53276112-5F34AC4A-26FE-4591-836D-32D01EF75F83Q53378480-91EB2173-FECF-4EF6-9AE9-951413C928EDQ53823696-972F70F4-0B15-441A-BF67-0E0C65828FA6Q55342497-53468442-7B39-4C26-B308-CEB6AC8D29D6Q57029311-560DB1BE-8242-408D-A0F3-745CC1009A9AQ57618480-B643C6F7-1397-4A5C-8668-714E8E5303B2Q57618496-BDAA7D8E-B2B7-4C64-9F0B-9644C2D8A774Q57618516-A00FF864-EAC1-4B62-8FA9-08EDA84B816AQ57618520-941F56B6-5C5C-4378-883D-050BCA0CB762Q57618540-D453C25D-8586-44DE-B1DD-38587338ED2DQ58732372-C4F61CD1-EAC4-4EC8-8770-9358C551C384Q63865939-89195002-E7B4-4606-976E-2FCAB85BB706Q64948376-66F4D1E7-D9DC-4E86-B762-A9E0912D9831Q80090038-E827004D-2CFB-4461-9DB8-358A6B6E785DQ80135619-F34406F3-1B07-416B-A1BD-CDC22CAC7E0EQ83395690-E499DD10-376C-446A-AE86-5DE274DC0AC1Q83589677-33FA3505-39E3-4A77-B948-2D6237817C2FQ84748292-A222885A-3FBA-4B63-84D1-B924261D404FQ87088337-231FD46C-67E2-478A-B0DD-E54889BFCBDA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Simon Bond
@ast
Simon Bond
@en
Simon Bond
@es
Simon Bond
@nl
type
label
Simon Bond
@ast
Simon Bond
@en
Simon Bond
@es
Simon Bond
@nl
prefLabel
Simon Bond
@ast
Simon Bond
@en
Simon Bond
@es
Simon Bond
@nl
P106
P31
P496
0000-0003-2528-1040